No predictive biomarker to indicate the clinical benefit of trifluridine/tipiracil (FTD/TPI) has been identified. Individual patient data from 329 patients from 2 randomized placebo-controlled trials were analyzed to determine the relationship between thymidine kinase 1 (TK1) expression and FTD/TPI efficacy in refractory metastatic colorectal cancer. Patients with high TK1 expression showed an improvement in overall survival when treated with FTD/TPI. Background: High thymidine kinase 1 (TK1) activity increases the incorporation of trifluridine (FTD) into DNA; thus, FTD antitumor activity is likely to increase in patients with high tumoral TK1 activity. To date, no established predictive biomarker to indicate the clinical benefit of FTD/tipiracil (TPI) has been identified. We aimed to determine the relationship between TK1 expression and FTD/TPI efficacy in refractory metastatic colorectal cancer. Patients and Methods: Individual patient data from 2 randomized placebo-controlled trials were analyzed. We measured TK1 protein expression in tumor tissue samples and its relationship with FTD/TPI clinical efficacy using overall survival (OS), progression-free survival, and disease control rate. Results: This study comprised 329 patients (FTD/TPI, 224; placebo, 105). FTD/TPI significantly improved OS versus placebo in the high-expression (cutoff 15%) TK1 group (median OS, 7.8 vs. 6.8 months; hazard ratio ¼ 0.65; 95% confidence interval, 0.46-0.93; P ¼ .018). The lowexpression (cutoff < 15%) TK1 group experienced a smaller OS benefit (9.3 vs. 7.4 months; hazard ratio ¼ 0.88; T.Y. and K.Yamazaki contributed equally to this work as first authors. Clinical Colorectal Cancer December 2018 -e719 95% confidence interval, 0.63-1.23; P ¼ .45). For patients who received placebo, the high-expression TK1 group had a slightly worse prognosis than the low-expression TK1 group. The tendency of FTD/TPI efficacy concerning progression-free survival and disease control rate was not similar to that concerning OS between groups. Conclusion: Patients with high TK1 expression showed an improvement in OS when treated with FTD/TPI. Further investigations are warranted to confirm this relationship.
Introduction
Metastatic colorectal cancer (mCRC) treatment has evolved significantly in the past 2 decades. Building on the backbone of chemotherapy with 5-fluorouracil/leucovorin with oxaliplatin, irinotecan, or both oxaliplatin and irinotecan, targeted agents have shown clinical benefit as first-line and subsequent therapies, including angiogenesis inhibitors (bevacizumab, aflibercept, and ramucirumab) and anti-epidermal growth factor receptor antibodies for wild-type RAS (cetuximab and panitumumab). The multityrosine kinase inhibitor regorafenib showed clinical benefit as a third-line and subsequent therapy. [1] [2] [3] [4] [5] [6] [7] [8] [9] More recently, the antiprogrammed cell death 1 monoclonal antibodies pembrolizumab and nivolumab were approved by the US Food and Drug Administration for the treatment of patients with unresectable or metastatic microsatellite instability (MSI) high/mismatch repair-deficient CRC. Although considerable efforts and resources have been dedicated to finding novel predictive biomarkers against mCRC, extended RAS/BRAF and MSI are the only validated biomarkers to date. [10] [11] [12] [13] The clinical benefits of trifluridine/tipiracil (FTD/TPI) include significant improvements in overall survival (OS) and progressionfree survival (PFS) as confirmed in randomized, placebocontrolled studies in mCRC patients in Japan (J003 study), multiple nations (Japan, US, Australia, and EU countries; RECOURSE study), and Asia (TERRA study). [14] [15] [16] Thus, FTD/TPI represents a standard treatment option as third-line and subsequent therapies for mCRC patients. FTD/TPI is a combination drug comprising the antineoplastic thymidine-based nucleoside analog FTD plus the thymidine phosphorylase inhibitor TPI at a molar ratio of 1:0.5 (weight ratio, 1:0.471). 17, 18 FTD is incorporated into DNA after phosphorylation by thymidine kinase 1 (TK1), causing DNA dysfunction. 18, 19 The mechanism of action of FTD/TPI is distinct from that of 5-fluorouracil, an analog of uracil and 5-fluoro-2 0 -deoxyuridine, which inhibits thymidylate synthase. 20, 21 Thymidine phosphorylase degrades nucleosides such as thymidine. TPI inhibits thymidine phosphorylase activity strongly and specifically, and inhibition of FTD degradation in living organisms has been confirmed. 18, 20 TK1 has a major role in the mechanism of action of FTD/TPI owing to FTD phosphorylation. High TK1 activity increases the incorporation of FTD into DNA; thus, FTD antitumor activity is likely to increase in patients with high tumoral TK1 activity. 22 To date, no established predictive biomarker to indicate the clinical benefit of FTD/TPI has been identified. The primary objective of the present study was to retrospectively determine the level of TK1 expression in tumor tissue samples and any relationship with FTD/ TPI clinical efficacy over placebo using individual patient data from 2 randomized placebo-controlled clinical trials. The exploratory objectives were to investigate genomic and genetic factors predicting responsiveness to FTD/TPI.
Patients and Methods

Trial Design and Participants
Data from 2 randomized, placebo-controlled trials were analyzed. 14, 15 In both studies, patients were randomized in a 2:1 ratio to receive either FTD/TPI plus best supportive care or placebo plus best supportive care. In the current study, mCRC patients refractory to standard chemotherapies and treated with either FTD/ TPI or placebo were assessed for treatment outcomes in relation to TK1 expression as a prespecified analysis. The trial was registered as follows: phase 2 (J-003) JapicCTI 090880, phase 3 (RECOURSE), ClinicalTrials.gov NCT01607957, and phase 3 PGx JapicCTI 121918.
Treatment
FTD/TPI (35 mg/m 2 per dose) was orally administered twice daily over 5 days for 2 weeks with 2 days of rest between weeks, followed by a 14-day resting period (1 treatment cycle). This treatment cycle was repeated every 4 weeks until disease progression or unacceptable toxicity.
Determination of TK1 Expression
Archival formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens collected during surgery or by biopsy were used. Immunohistochemistry was performed in the central laboratory to evaluate the TK1 expression. All evaluations were blinded. Detection was performed using anti-human TK1 rabbit polyclonal antibody (Taiho Pharmaceutical) and anti-human TK1 mouse monoclonal antibody (Immuno-Biological Laboratories) in phase 2 and 3 studies, respectively. The TK1 antibodies were validated via multiple tissue microarray samples carried out by independent immunohistochemistry experts. The area stained in tumor cells was classified according to intensity by 5% intervals and scored as 0, 1þ, 2þ, or 3þ by independent pathologists. Positively stained cells were defined as those with a staining intensity of 2þ or 3þ. Occupancy rates of the areas scored as 2þ and 3þ in tumor cells were calculated (low-scoring cells with 0/1þ expression were excluded) and divided into 2 groups (high or low TK1 expression) (Supplemental Figure 1 in the online version).
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Relationship Between TK1 Expression and Clinical Efficacy
The OS, PFS, and disease control rate (DCR) were analyzed to evaluate differences in treatment effect by TK1-defined subgroup (high or low TK1 expression).
Exploratory End Points
For the exploratory end points, next-generation sequencing (NGS) and MSI analyses were centrally conducted. Using the QIAamp DNA FFPE Tissue Kit (Qiagen), genomic DNA was extracted from the FFPE slides of tumor tissue samples containing at least 70% of tumor cells (verified microscopically). Samples were checked for quality using PCR. The TruSight Tumor Panel (Illumina) is an enrichment system targeting 174 amplicons within 26 well-known genes related to various types of cancer (Supplemental Table 1 in the online version). The resulting Variant Call Format files generated by MiSeq Reporter (Illumina) were analyzed using VariantStudio Data Analysis v.2.2. Software (Illumina). The OS, PFS, and DCR were calculated for each treatment group and each nonsynonymous gene mutation subgroup (mutant or wild-type). For MSI status, DNA samples were PCR amplified using primers fluorescently labeled for the mononucleotide repeat markers of 5 loci (NR21, NR24, BAT25, BAT26, and MONO27), and then subjected to capillary electrophoresis using the MSI Analysis System (Promega).
Statistical Analysis
This study was not specifically powered to assess the efficacy of FTD/TPI in any TK1-defined subgroups, and no sample size calculations were performed for our analyses. Patients whose TK1 expression was assessed were included in the current study. The analysis set for OS and PFS comprised the TK1-defined population. The analysis set for DCR comprised patients who were evaluable for both TK1 expression and tumor response. For OS and PFS, hazard ratios (HR) for study treatment were estimated using multivariate Cox proportional hazards modeling, with the covariates of TK1 protein expression level and the other baseline factors selected using a stepwise method. Interactions between study treatment and TK1 protein expression were assessed in the same manner. The DCR odds ratio was estimated using a multivariate logistic regression model. NGS to identify genetic mutations was conducted only on the evaluable population of the phase 3 study.
Sensitivity analysis was conducted to determine whether differences in characteristics between the study populations influenced the OS and PFS. The HR of treatment efficacy was estimated by Cox proportional hazard modeling with the following 5 factors used as covariates: J-003 or RECOURSE study, number of previous treatments, previous treatment with bevacizumab, previous treatment with anti-EGFR antibody, and presence of KRAS mutation.
To validate the predictive role of TK1 in FTD/TPI treatment in an explorative manner, the datasets of the TK1-defined population from the J-003 and RECOURSE studies were randomly divided into 2 equal datasets: a training cohort (n ¼ 166) and a validation cohort (n ¼ 163). The HRs for OS and PFS in each TK1-defined subgroup (high/low) were estimated in each cohort. Simulations were also performed in the same manner.
A 2-sided P value was calculated for each statistical test. No adjustments were made for multiple comparisons. All statistical analyses were performed by SAS 9.2 (SAS Institute).
Ethical Considerations
The studies were carried out in accordance with good clinical practice guidelines and the Declaration of Helsinki and were approved by the institutional review boards of participating institutions. All patients provided written informed consent for the optional pharmacogenetics studies, in addition to that provided for the main phase 2 and phase 3 studies. Figure 2 in the online version). The phase 2 and 3 studies comprised 150 and 179 participants, respectively. Overall, 224 patients received FTD/TPI and 105 received placebo. Gene mutation analysis by NGS was evaluable in 159 patients (109, FTD/ TPI; 50, placebo), all of whom were participants in the phase 3 study. Table 1 shows the baseline characteristics of participants in the FTD/TPI and placebo groups in the combined intent-to-treat population, TK1-defined population, and gene mutation analysis evaluable population. The characteristics in the FTD/TPI and placebo groups in the TK1-defined and gene mutation analysis evaluable populations were generally balanced. Baseline patient characteristics were also generally similar among the 3 populations. The HRs of OS and PFS were similar between the combined intentto-treat and TK1-defined populations, although those in the gene mutation analysis evaluable population were slightly different. In the TK1-defined populations, the OS and PFS significantly improved in the FTD/TPI group compared to the placebo group ( Figure 1A and B) . The results of the sensitivity analysis showed that there was almost no difference in HR values for OS and PFS before adjusting compared to after adjusting for patient characteristics (data not shown).
Results
TK1 expression was evaluable in 329 patients (Supplemental
In the immunohistochemistry studies, the mean and median percentages of positively stained cells were 15.8% and 10%, respectively. Given that the median to mean TK1 expression ranged from 10% to 15.8%, 15% was chosen as the cutoff point for high or low TK1 expression (high: 15%; 160 patients, low: < 15%; 169 patients) (Supplemental Table 2 in the online version). There was no bias in patients' characteristics between the FTD/TPI and placebo groups as a result of dividing the patient populations on the basis of TK1 expression levels.
Predictive Utility of TK1
As shown in Figure 2A , at the 15% cutoff, FTD/TPI significantly improved OS compared to placebo (median OS of FTD/TPI vs. placebo, 7.8 vs. 6.8 months; HR ¼ 0.65; 95% confidence interval, 0.46-0.93; P ¼ .018) in the high TK1 expression group, and showed a greater OS benefit than the low TK1 expression group (9.3 vs. 7.4 months; HR ¼ 0.88; 95% confidence interval, 0.63-1.23; P ¼ .45).
A significant improvement in PFS was shown with FTD/TPI compared to placebo in both the high TK1 expression (median PFS of FTD/TPI vs. placebo, 2.1 vs. 1.1 months; HR ¼ 0.37, 95%
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Clinical Colorectal Cancer December 2018 -e721 Figure 2B ). The PFS and DCR benefit was similar between the high and low TK1 expression groups, contrary to the findings for OS. Figure 3A and B show median time and HR for OS and PFS according to TK1-defined subgroups.
Regarding the potential utility of TK1 as a biomarker for FTD/TPI efficacy, while OS was improved in patients with high TK1 expression receiving FTD/TPI in every subgroup, a different trend was observed in terms of PFS, with patients with high TK1 expression performing less well. The DCR of FTD/TPI was significantly higher than that of placebo, regardless of TK1 expression at the 15% cutoff point (Supplemental Figure 3 in the online version). A validation analysis, in which the patients were divided into a training cohort and a validation cohort, showed similar results (Supplemental Table 3 in the online version).
Prognostic Utility of TK1
Patients with high TK1 expression who received placebo had a slightly poorer prognosis than those with low TK1 expression in terms of OS by multivariate analysis (Figure 4) . The numbers of patients with RAS and BRAF mutations, some of the generally known prognostic factors, were well-balanced between treatment groups (data not shown).
Clinical Significance of NGS Profile
Evaluable patients for MSI and NGS were analyzed for the exploratory objectives. Ten gene mutations were identified overall (Supplemental Figure 4 in the online version). Of these, 5 occurred at a frequency greater than 10% in the FTD/TPI group [TP53, APC, RAS (KRAS/NRAS ), PI3CA, and FBXW7]. Although a trend toward better OS was observed in patients with the RAS wild-type gene, there was no clear relationship between gene status and clinical efficacy (data not shown). Gene mutations [TP53, APC, RAS (KRAS/NRAS ), PI3CA, and FBXW7] were added as covariates in a multivariate analysis to evaluate prognosis; however, all gene mutations were excluded from the model by stepwise selection. MSI analysis was conducted in 155 DNA samples from the PGx study in the phase 3 study. However, the only patient with MSIhigh was in the placebo group, so a relationship with efficacy was not analyzed.
Discussion
The purpose of this study was to determine whether there was any relationship between TK1 expression and FTD/TPI clinical efficacy in mCRC patients using data from 2 clinical trials. OS data in the patients receiving placebo indicated that high TK1 expression may be a marker of poor prognosis. Although similar findings have previously been reported in several cancers, there are no reports in CRC. [23] [24] [25] Regarding the potential clinical utility of TK1 as a biomarker for FTD/TPI efficacy, a greater OS benefit was observed in patients with high TK1 expression receiving FTD/TPI at the 15% cutoff point, while PFS and DCR benefits in patients receiving FTD/TPI were similar between high and low TK1 expression subgroups. The results of sensitivity analysis showed that the effect of differences in patient characteristics between the study populations of 2 randomized clinical trials on the OS and PFS was small (data not shown), and thus, do not explain the differences in OS and PFS benefits between the patients in the present studies. The results from the validation analysis supported the results of the multivariate analysis at the 15% cutoff point. A potential reason why the PFS and DCR results differed from the OS results is that tumors with low TK1 expression are more indolent than tumors with high TK1 expression. As the incorporation of FTD/TPI in tumors with low TK1 expression is possibly lower, the pharmaceutical effect of FTD/TPI might also be lower; however, tumors with low TK1 expression might present slow growth because of their indolence. Therefore, tumors with low TK1 expression might Figure 1 Kaplan-Meier Curves for (A) OS and (B) PFS in TK1-Defined Population (FTD/TPI Versus Placebo). Horizontal axes of OS curve and PFS curve were truncated at 24 months and 12 months, respectively, because only a few patients were censored over boundary
Abbreviations: CI ¼ confidence interval; FTD/TPI ¼ trifluridine/tipiracil; HR ¼ hazard ratio; m ¼ median; OS ¼ overall survival; PFS ¼ progression-free survival; TK1 ¼ thymidine kinase 1.
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show a similar PFS and DCR benefit compared to tumors with high TK1 expression. Regarding mutation analysis, no particular tendency was observed for the distribution of genetic mutations in the FTD/TPI and placebo groups (Supplemental Figure 4 in the online version) . The distribution of mutations between high and low TK1 expression subgroups did not show a particular tendency. No differences were observed in the ratio or proportion of mutations between the FTD/TPI and placebo groups (data not shown). The exploratory analyses in this study did not identify any specific gene correlating with the clinical efficacy of FTD/TPI.
Previous studies of FTD/TPI with mCRC observed that neutropenia, after initiating FTD/TPI treatment, was associated with better prognosis in refractory mCRC patients. 26, 27 Thus, neutropenia might be a surrogate marker for adequate FTD/TPI dosing. As it is currently not possible to predict the efficacy of FTD/ TPI before the administration of treatment, further study of biomarkers such as TK1 is warranted.
The study is limited by its relatively small sample size due to TK1-defined subgroup analyses, and the fact that it was not prospectively designed to evaluate any relationship between TK1 expression and efficacy. Furthermore, it was unknown whether the tissue samples used to measure TK1 expression were collected from the primary tumor or from metastases in the pooled studies; this may have caused potential bias. In the J-003 study, assessment of MSI could not be conducted as no tissue samples were collected. Finally, the study comprised only Japanese patients, thus limiting ethnic generalizability. Larger studies in patient populations comprising various ethnicities would, therefore, be of value.
Conclusion
Overall, the findings indicate that high TK1 expression could be a marker of poor prognosis in terms of OS in refractory mCRC patients. On the basis of OS data comparing FTD/TPI with placebo, high TK1 expression in patients treated with FTD/TPI might be suggestive of better outcomes. However, further investigations 
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Clinical Practice Points
Several studies have shown that FTD/TPI provides clinical benefits in terms of significant improvements in OS and PFS in mCRC patients. However, to date, no established predictive biomarker has been identified that can indicate the clinical benefit of FTD/TPI. TK1 plays a major role in the mechanism of action of FTD/TPI owing to FTD phosphorylation. High TK1 activity increases the incorporation of FTD into DNA; thus, FTD antitumor activity is likely to increase in patients with high tumoral TK1 activity. Our findings showed that high TK1 expression could be a marker of poor prognosis in terms of OS in refractory mCRC patients and that FTD/TPI treatment may be more effective in improving OS among patients with high TK1 expression versus those with low TK1 expression. The assessment of TK1 expression as a predictive biomarker of the clinical benefit of FTD/TPI may be useful in clinical practice to determine which colorectal cancer patients are more likely to benefit from FTD/TPI treatment.
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Supplemental Figure 4 Mutation Frequency in FTD/TPI and Placebo Groups Ten genes were identified as having mutations. Genes with > 10% mutation frequency in FTD/TPI group were TP53, APC, RAS, PIK3CA, and FBXW7 Supplemental 
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